Beyond the Early Signal: What Durable Progress Looks Like in Blood Cancer Research

In hematology, the most important questions about a therapy’s value are rarely answered in a single early readout. They often take time, repeated study, and maturing evidence to answer:

• How durable is disease control?
• Which patients are most likely to benefit?
• What does longer follow-up reveal about safety, depth of response, and treatment fit over time?

EHA has served as a forum for these questions for more than 30 years, bringing the global hematology community together to examine not only what is new, but what holds up. It is where findings that begin as early signals become (or do not become) the foundation for clinical practice.

At BeOne, this is also how we think about progress. Advancing blood cancer care isn’t about just generating data; it’s about building evidence strong enough to clarify how therapies may perform across patients, clinical contexts, and treatment decisions that grow more consequential over time.

Long-term follow-up reveals what early data cannot. In blood cancers, where patients may remain on therapy for years or move through multiple lines of treatment over their lives, the questions that most affect clinical practice often become answerable only with time.

BeOne’s EHA 2026 program includes follow-up data from our CLL research now extending beyond six years — among the longest reported for a next-generation approach in this setting. One distinctive element of this dataset is its scope: it includes one of the largest and longest-followed cohorts of patients aged 80 and older reported in a Phase 3 CLL study.

This matters because CLL is a disease of older adults. The median age at diagnosis is 70, yet clinical trial populations have historically underrepresented patients in their 70s and beyond — the very patients most physicians treat most often. These patients frequently carry a substantial burden of comorbidities relevant to treatment decisions in CLL.

Long-term data in this population shows something clinically meaningful: durable disease control appears possible even in patients who carry significant high-risk features alongside advanced age. For clinicians and families weighing treatment decisions, that evidence provides a different quality of confidence than early-signal data can offer. It reflects what treatment looks like not in an idealized population, but in one that more closely resembles real-world care.

CLL and other B-cell malignancies are heterogeneous. No single mechanism or treatment approach answers every clinical need across all patients, risk profiles, or points in the treatment journey.

BeOne’s EHA 2026 program reflects that breadth, with 37 abstracts spanning CLL, small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL), and crossing three foundational mechanisms in B-cell cancer: BTK inhibition, BCL-2 inhibition, and BTK degradation.

This multi-mechanism research footprint matters because it allows the field to build a more connected understanding of disease biology, treatment sequencing, and where each approach may matter most. Some patients may need sustained disease suppression. Others may benefit from combination approaches designed to achieve deep responses that hold up after treatment ends. And for patients whose disease has progressed or become resistant to prior therapies, next-generation approaches designed to address that resistance are increasingly important.

Research across mechanisms is not just a measure of portfolio breadth. It reflects a commitment to addressing the complexity of B-cell malignancies across patient populations, treatment settings, and points in the treatment journey, so clinicians have more and better options as care continues to evolve.

Rigorous evidence generation in hematology is not just about running studies. It is about asking harder questions and designing research to answer them.

That means testing whether early signals translate into meaningful durability. Does a deep initial response hold up when therapy ends? Does it hold up in patients with the highest-risk biological features? Does it hold up in populations that often define real-world practice but have historically been underrepresented in pivotal trials?

It also means testing findings beyond the trial setting. Real-world data across hundreds of thousands of patients can reveal how therapies perform outside controlled enrollment conditions, in more diverse care settings, and over longer periods than any single trial can follow. When trial results and real-world evidence point in the same direction, the clinical case becomes stronger.

Rigorous hypothesis testing in blood cancer also means designing research with comparison in mind — studying not only whether an approach works, but how it compares to alternatives and what distinguishes different mechanisms from one another. That discipline allows the field to move from asking “does this work?” to asking “for whom, compared to what, and for how long?”

One important and underexplored dimension of this evidence involves understanding what patients themselves prioritize. Research drawing on tens of thousands of patient conversations across multiple European countries finds that safety and effectiveness are consistently the top drivers of treatment choice, ranked significantly higher than treatment duration. This patient-reported perspective reinforces what rigorous clinical evidence increasingly shows: durable, well-tolerated disease control is what matters most, and evidence that holds up over time is the standard the field should be held to.